Heterogeneity of clinical data management solutions
Our survey covers many large European countries and some of the smaller ones (Figure
1). To our knowledge, this is the first time that an overview is published on CDMS tools, DM resources and quality management procedures within such a large number of academic clinical centres in Europe. In contrast, most surveys published have been concerned only with the proportion of electronic data capture in relation to paper based data collection. Recently the number of clinical trials conducted with electronic data capture has been increased considerably. A survey showed that between 2008 and 2009 45% of respondents already conducted more than 50% of their trials using EDC [
11]. A recent analysis of clinical trials in Canada showed that the adoption of EDC systems in clinical trials is higher than indicated in the literature [
12]: it was estimated that 41% of clinical trials were using an EDC system. Though, trials funded by academic institutions and government were less likely to use an EDC system compared to those sponsored by industry.
Clearly, electronic data capture has reached academic clinical research centres. Our survey shows that the DM situation in European clinical centres and the CDMS in use are surprisingly heterogeneous. In fact, the number of different solution seems to have increased between 2008 and 2009 (Table
3). Not only is no single CDMS product in predominant use, but also different concepts are used for DM (e.g. groupware systems, clinical information systems, data analysis systems are used for study data collection). A large part of clinical centres uses their own developed solution or a single solution not used by any other centre. Open Source CDMS may be an alternative [
13], but have not yet been introduced on a large scale so far. Only about 10% of centres use an Open Source solution including GCP BASE™, PhOSCo™, openCDMS™ (PsyGrid™) and EpiData™. OpenClinica™ an Open Source solution which has recently gained in popularity is only used by a single centre. Nonetheless, we know of several centres that have installed OpenClinica™ in addition to their routine system for evaluation.
Although many different CDMS are in use, solutions which are represented strongly in pharma industry (e.g. Medidata™, PhaseForward™, and Oracle Clinical™) were not mentioned. On the other hand, our survey covers many CDMS which have never been mentioned in previous surveys or market analyses [
14‐
16]. A reason for this may be that many vendors of commercial solutions seem to focus for the most part on clients in pharma industry with their considerable financial resources and offer features, like a product or active substance level, that are not useful in academic trials. In addition, commercial software may be disadvantageous for academic research mainly because of high costs and because of risks regarding delivery and future software maintenance. Furthermore, software licences should not restrict the integration with other systems and the upgrading of the IT infrastructure of academic centres. A reason for the high degree of heterogeneity may be the necessity to use specific CDMS solutions for disease specific networks (e.g. cancer, paediatrics, and psychiatrics). For academic trials the shortening of the time to market for a product cannot be the main objective for using a CDMS. For academic clinical trials it is data quality, better recruitment and a more efficient trial conduct that counts. The prime importance of data quality for academic trials is illustrated by the fact, that data analysis software and even data mining solutions are used as CDMS (e.g. SAS™, PheedIT™, SPAD™). Because ECRIN data centres will support European international clinical trials, the considerable heterogeneity in their available DM resources and employed solutions may turn out to be a hindrance for international cooperation and trial data exchange. This may indicate the necessity to further the implementation of common data standards like CDISC (Clinical Data Interchange Standard Consortium) in ECRIN.
The use of CDMS in clinical trials are characterised by the impact of regulations on DM (e.g. 21 CRF Part 11, EU GMP Guideline Vol. 4, Annex 11 Computerized Systems, GCP, data protection laws, e-signature requirements). For clinical centres employing CDMS it becomes necessary to implement best practices for CRF design, query resolution, and study start-up in an EDC environment, including user acceptance testing, system validation, creation of a data management plan and training of investigators in the use of the application. These requirements may cause considerable pressure on the DM resources of a data centre. To provide the necessary quality ECRIN data centres have to accomplish best practices with rather limited resources. Because the most important factors for the quality of clinical trial conduct are good clinical project management together with efficient clinical data management, clinical trial operations depend increasingly on the quality of the IT infrastructure. To conduct international clinical trials IT-based collaborative support can become even more useful because it enables remote monitoring, adverse event notification, and remote review of clinical operations across international sites and various time zones. But our survey shows that most centres are focused only on the core functions of DM (data collection, query management, reporting). This limitation may be necessary in light of the limited resources available in ECRIN data centres, but there is also the necessity to improve quality management by harmonisation. Standards with respect to DM should be promoted in all national networks of clinical trial units and clinical research centres and resources for common quality management should be exchanged. Because of the heterogeneity in CDMS the support of data exchange standards (CDISC, HL7, IHE) becomes a necessity for cooperation in international clinical trials. Therefore, ECRIN centres should try to jointly use DM resources and enforce the support of CDISC standards.
Although highly sophisticated, some web-based EDC systems still seem to show impairments [
17], notably that systems are not robust enough to handle the workload (e.g. slow web page refreshing rate), that EDC systems support different versions of basic software (e.g. internet browsers) and that CRF pages are not displayed correctly (e.g. missing data field boxes). In addition, EDC systems often may generate unnecessary queries. To avoid these problems, quality management, best practices and training will be important aspects of DM services of ECRIN data centres. Our survey shows that human resources in many ECRIN centres are often small and that some deficits in quality management exist, especially in the use of system validated CDMS and the documented evidence for data management audits. For this reason the ECRIN working group will design and implement an independent certification process for ECRIN centres to certify centres that are qualified to conduct GCP compliant international trials [
18]. To receive a certificate evidence for comprehensive quality management will be of utmost importance and available resources and workload will be critical factors.
ECRIN centres should prepare themselves for new developments in the area of clinical trial DM. Our survey shows that to a large degree only basic functionalities of CDMS are supported. But in future, interfaces between clinics, medical practices, and laboratories, as well as integration with site management, electronic patient reported outcomes (ePRO) and data warehouses will become necessary components. Especially, electronic health records (EHR) will be used increasingly for data collection in clinical trials; because the EHR does not interrupt the investigator's workflow in a way the EDC system does [
19]. There will be the need to have CDMS available in ECRIN data centres that will support such EHR based data collection in the future. Therefore, in the heterogeneous CDMS environment of ECRIN the dedicated ECRIN data centres should encourage the use of clinical research standards that allow for interoperability with the EHR (e.g. CDISC healthcare link). This may even contribute to the streamlining of clinical research and therefore improve healthcare for patients.
For the implementation and the use of a CDMS an ethical approval is in general not necessary. Nonetheless, because clinical data management handles and processes human data, it must comply with high ethical standards. The ethical aspects are covered by the need for GCP compliance of any CDMS that is used in a clinical trial. GCP is a standard for design, conduct, performance, monitoring, auditing, recording, analyses, and reporting of clinical trials. Implementation of GCP not only provides assurance that trial data are credible and accurate, but also that the rights, integrity, and confidentiality of trial subjects are protected [
20]. In topic 5.5.3 GCP regulates details of using electronic trial data and electronic trial data systems (e.g. audit trail, SOPs, security system, backup). In addition, European Directive 2001/20/EC [
21] regulates certain ethical aspects of clinical data management by requiring the existence of safeguards for the rights of trial subjects to privacy and to the protection of their personal data. GCP compliance and data security is guaranteed by a process called "system validation" in which requirements and specifications of CDMS are evaluated. Complete system validation documentation must be produced in case a centre is audited by authorities. In this way, an extensive certification process may support ethical considerations when using a CDMS, ensuing that patient data are collected correctly and used adequately.